The 3 most recent market catalysts affecting $LKFT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45
RBC Capital analyst Brian Abrahams upgraded Lakefront Biotherapeutics (LKFT) from 'Sector Perform' to 'Outperform' and raised the price target from $26 to $45. This is a significan…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 55
Bank Of America Raises Lakefront Biotherapeutics Stake Above To 10.11%
Bank of America Corporation has disclosed an increase in its ownership of Lakefront Biotherapeutics NV, now holding 10.11% of the voting rights. This crossing of the 10% transparen…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 95
Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate
Lakefront Biotherapeutics (LKFT) reported Q2 earnings per share of $0.29, significantly beating the analyst consensus estimate of a $(13.52) loss. Sales also came in strong at $21.…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.